Omics Technology facility

核心技术开发一直是本财政年度的主要重点。我们正在建立基于ngs的技术，以发现癌症驱动因素，并了解生物机制。具体而言，下列技术已确立或接近确立。1. NGS用于癌症突变检测。我们采用了DNA和RNA外显子组测序的方法，目的是检测SNV、缺失和插入。2. NGS用于表达和融合检测。实验室的工作人员接受了RNA外显子组测序的培训，用于检测融合和表达分析。3. 表观遗传调控。我们采用了两种不同的chip-seq方法，包括通过微球菌核酸酶和转座进行抗体介导的DNA切割。4. 癌症基因面板的靶向测序t细胞介导的肿瘤抗原应答相关基因的定制检测开发和测序分别对NGS方法的预期研究或临床应用进行验证完善NGS数据分析的分析管道。8. 使用FISH、RNAScope和其他基于荧光的方法研究肿瘤异质性。

Core technology development has been the main focus during this fiscal year. We are in the process of establishing NGS-based technologies for the discovery of cancer drivers, and for understanding biological mechanisms. Specifically, the following technologies are established or near establishment. 1. NGS for cancer mutation detection. We adapted methods for both DNA and RNA Exome sequencing aimed for detection SNV, deletion, an insertion. 2. NGS for expression and fusion detection. The staff in the lab were trained for RNA Exome seq for the detection of fusions, and for expression analysis. 3. Epigenetic regulation. We adapted two different methods for chip-seq, including antibody-mediated DNA cutting by micrococcal nucleases and transposes. 4. Targeted sequencing of cancer gene panels 5. Customized assay development and sequencing of genes involved in T-cell mediated responses against tumor antigens 6. Validation of the NGS methods for their intended research or clinical use, respectively 7. Refining the analytical pipelines for NGS data analysis. 8. Investigating tumor heterogeneity using FISH, RNAScope, and other fluorescent based methods.